Eisai Presents Breadth of Data Across Neurology Portfolio, Including Alzheimer's Disease, Insomnia and Epilepsy
Eisai Presents Breadth of Data Across Neurology Portfolio, Including Alzheimers Disease, Insomnia and Epilepsy Twenty-one presentations featuring data and information on investigational lecanemab in early Alzheimers disease, DAYVIGO® (lemborexant) CIV in insomnia, FYCOMPA® (perampanel) CIII in epilepsy and investigational lorcaserin in Dravet Syndrome News provided by Share this article Share this article WOODCLIFF LAKE, N.J., April 16, 2021 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical...
Source: prnewswire.com